DNTH Stock Dianthus Therapeutics (DNTH, $25.63) entered Downtrend as Momentum indicator drops below 0 level on May 17, 2024

GET DAILY SIGNALS

Get AI intraday signals

DNTH - Dianthus Therapeutics

Momentum signal

View

Odds of DOWN Trend

Price: $25.63

Daily change: -$0.62 (-2.36%)

Daily volume: 88.7K

Capitalization: $752.2M

Industry: Biotechnology

DNTH sees MACD Histogram just turned negative

DNTH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 12, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on DNTH as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

DNTH moved below its 50-day moving average on November 12, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNTH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for DNTH crossed bullishly above the 50-day moving average on October 28, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DNTH advanced for three days, in of 272 cases, the price rose further within the following month. The odds of a continued upward trend are .

DNTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 157 cases where DNTH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DNTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.233) is normal, around the industry mean (14.655). P/E Ratio (3.530) is within average values for comparable stocks, (96.848). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.824). DNTH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (133.333) is also within normal values, averaging (218.428).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.